Pexidartinib
Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: CML-261, pexidartinib hydrochloride, PLX3397, turalio
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Pexidartinib is an onp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 3A Inducers. DrugCentral lists 15 molecular targets, including PRKCQ, PDGFRA and CSF1R. Recorded indications include Tenosynovial giant cell tumor.
- Approval status: onp (first approved 2019 by the FDA).
- Drug class: Kinase Inhibitor.
- Mechanism of action: Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 3A Inducers.
- Molecular targets: PRKCQ, PDGFRA, CSF1R and Csf1r (15 listed in DrugCentral).
- Indications: Tenosynovial giant cell tumor.
- ATC code: L01EX15 (Other protein kinase inhibitors).
- Molecular formula: C20H15ClF3N5; molecular weight 417.82 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Tenosynovial giant cell tumor
Mechanism & targets
| Mechanism of action (MoA) | Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 3A Inducers; Kinase Inhibitors; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors |
|---|---|
| Established pharmacologic class | Kinase Inhibitor |
Molecular targets (15)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Protein kinase C theta type | PRKCQ | unknown | Kd 8.22 |
| Platelet-derived growth factor receptor alpha | PDGFRA | unknown | IC50 8.02 |
| Macrophage colony-stimulating factor 1 receptor | CSF1R | inhibitor | IC50 7.88 |
| Macrophage colony-stimulating factor 1 receptor | Csf1r | unknown | IC50 7.85 |
| Mast/stem cell growth factor receptor Kit | KIT | inhibitor | IC50 7.56 |
| Platelet-derived growth factor receptor beta | PDGFRB | unknown | IC50 7.44 |
| Cyclin-dependent kinase 19 | CDK19 | inhibitor | IC50 6.85 |
| Receptor-type tyrosine-protein kinase FLT3 | FLT3 | inhibitor | IC50 6.79 |
| Vascular endothelial growth factor receptor 2 | KDR | inhibitor | IC50 6.36 |
| Aurora kinase B | AURKB | unknown | IC50 6.19 |
| Tyrosine-protein kinase Lck | LCK | inhibitor | IC50 6.07 |
| Vascular endothelial growth factor receptor 1 | FLT1 | inhibitor | IC50 6.06 |
| NT-3 growth factor receptor | NTRK3 | inhibitor | IC50 6.05 |
| Uncharacterized protein FLJ45252 | — | unknown | Kd 5.84 |
| AP2-associated protein kinase 1 | AAK1 | unknown | Kd 4.86 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-08-02 | FDA | — | DAIICHI SANKYO INC | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01EX15 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Hair colour changes | 837.2 |
| Product dose omission issue | 243.6 |
| Aspartate aminotransferase increased | 161.0 |
| Alanine aminotransferase increased | 133.3 |
| Gamma-glutamyltransferase increased | 129.3 |
| Blood alkaline phosphatase increased | 121.8 |
| Fatigue | 103.8 |
| Periorbital swelling | 103.1 |
| No adverse event | 88.6 |
| Therapy cessation | 86.5 |
| Pruritus | 61.1 |
| Blood bilirubin increased | 60.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Pexidartinib is on its molecule page.
| Molecular formula | C20H15ClF3N5 |
|---|---|
| Molecular weight | 417.82 g/mol |
| CAS number | 1029044-16-3 |
| InChIKey | JGWRKYUXBBNENE-UHFFFAOYSA-N |
| PubChem CID | 25151352 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Pexidartinib used for?
DrugCentral lists the following indications for Pexidartinib: Tenosynovial giant cell tumor.
How does Pexidartinib work?
Pexidartinib is classified as Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 3A Inducers; its molecular targets in DrugCentral include PRKCQ, PDGFRA, CSF1R (inhibitor) and Csf1r.
When was Pexidartinib first approved?
Pexidartinib was first approved by the FDA in 2019.
What drug class does Pexidartinib belong to?
Pexidartinib is in the Kinase Inhibitor class.
What is the chemical formula of Pexidartinib?
Pexidartinib has the molecular formula C20H15ClF3N5 and a molecular weight of 417.82 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5343 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3813873 — compound record and bioactivity
- PubChem CID 25151352 — chemical identifiers
- DrugBank DB12978 — drug record
- FDA UNII 6783M2LV5X — substance identity
- DailyMed: FDA labels for Pexidartinib — current prescribing information (label search)
- UniProt Q04759 (PRKCQ) — target protein
- UniProt P16234 (PDGFRA) — target protein
- UniProt P07333 (CSF1R) — target protein
- UniProt P10721 (KIT) — target protein
- UniProt P09619 (PDGFRB) — target protein
- UniProt Q9BWU1 (CDK19) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.